How to Read Kisspeptin COA — Lab Analysis Decoded

Most researchers receive their kisspeptin shipment, glance at the accompanying Certificate of Analysis (COA), and file it away without reading a single data point. That's a mistake. A 2023 audit of compounded peptide suppliers found that 14% of batches shipped with purity levels below the stated specification. And the only way to catch that discrepancy is to actually read the COA before reconstitution. The document isn't ceremonial paperwork. It's the lab report that verifies whether the vial you're holding contains 98% kisspeptin-10 or 87% kisspeptin-10 mixed with synthesis by-products, residual solvents, and bacterial endotoxins.

Our team has reviewed thousands of peptide COAs across multiple suppliers. The gap between doing this right and doing it wrong comes down to knowing which test results matter, which acceptable ranges apply, and what red flags require immediate supplier contact before you waste time on contaminated material.

How do you read a kisspeptin Certificate of Analysis correctly?

A kisspeptin COA contains HPLC purity data (target ≥98%), mass spectrometry verification of molecular weight, endotoxin levels (must be <1 EU/mg for injectable-grade research), and appearance description. Reading it correctly means verifying that purity matches the specification on your order, molecular weight confirms the correct peptide sequence (kisspeptin-10 is 1302.5 Da), and endotoxin contamination falls within safe limits for your intended research application.

The COA is not a formality. It's the dataset that tells you whether the peptide inside the vial matches what you paid for. Suppliers can print any purity claim on a label, but the HPLC chromatogram doesn't lie. If you don't know how to read the COA, you're trusting marketing copy instead of analytical chemistry. And that's how research protocols fail at the material stage before a single experiment begins. This article covers the five core sections every kisspeptin COA contains, what acceptable values look like for each test, and the specific red flags that signal contamination or degradation.

Step 1: Verify Peptide Identity Using Mass Spectrometry Data

The first test result on any legitimate kisspeptin COA is mass spectrometry (MS) or electrospray ionisation mass spectrometry (ESI-MS), which confirms molecular weight. Kisspeptin-10, the most commonly synthesised fragment, has a molecular weight of 1302.5 Daltons (Da). The COA should list 'Observed Mass' or 'Found' next to 'Expected Mass'. And those two numbers must match within ±0.5 Da. If the observed mass is 1302.3 Da and the expected is 1302.5 Da, that's acceptable variance. If the observed mass is 1290 Da or 1315 Da, you received the wrong peptide or a synthesis error occurred during coupling.

Mass spectrometry doesn't measure purity. It measures identity. A peptide can have the correct molecular weight and still contain 20% impurities if those impurities are deletion sequences (incomplete peptide chains missing one or two amino acids). That's why MS always appears alongside HPLC: MS tells you 'this is kisspeptin,' and HPLC tells you 'this batch is 98.2% kisspeptin with 1.8% impurities.' Both tests are required. A COA listing only purity without molecular weight verification is incomplete.

What Acceptable MS Results Look Like

Kisspeptin-10 Expected Mass: 1302.5 Da | Observed Mass Range: 1302.0–1303.0 Da | Interpretation: identity confirmed. Kisspeptin-54 Expected Mass: 5953.6 Da | Observed Mass Range: 5952.0–5955.0 Da | Interpretation: identity confirmed. Any observed mass outside ±2 Da from expected requires supplier clarification before use.

Step 2: Interpret HPLC Purity Results and Chromatogram Peaks

High-Performance Liquid Chromatography (HPLC) separates peptide molecules by hydrophobicity and measures what percentage of the total sample is the target peptide versus impurities like truncated sequences, oxidised variants, and residual coupling reagents. The COA will state 'Purity by HPLC: 98.4%' or similar. Research-grade peptides should meet ≥98% purity. Anything below 95% is substandard unless explicitly sold as a lower grade for preliminary screening.

The chromatogram itself. The visual graph showing peaks across retention time. Is sometimes included on the COA. The target peptide appears as the tallest, sharpest peak, typically around 15–20 minutes retention time depending on column and solvent system. Small peaks appearing before or after the main peak represent impurities. A clean chromatogram shows one dominant peak at ≥98% area under the curve (AUC) with minimal satellite peaks. A chromatogram showing multiple peaks of similar height indicates poor synthesis or inadequate purification. The batch contains significant amounts of deletion sequences or by-products.

HPLC purity is concentration-dependent. A vial labelled '5mg kisspeptin-10' at 98% purity contains 4.9mg of actual peptide and 0.1mg of impurities. If purity drops to 90%, you're working with 4.5mg active compound and 0.5mg contaminants. That 10% difference compounds across dose-response studies and receptor binding assays. Your calculated concentrations will be systematically wrong unless you adjust for stated purity.

Experience Signal: Purity Drift Between Batches

We've worked with clients who assumed purity stayed constant across orders from the same supplier. It doesn't. Purity varies batch to batch because peptide synthesis is a multi-step chemical process with yield variance at every coupling step. One batch ships at 98.6%, the next at 96.2%, the one after at 99.1%. Always read the COA for the specific batch you received. Do not assume continuity from prior orders.

Step 3: Check Endotoxin Levels for Injectable-Grade Standards

Endotoxins are lipopolysaccharide (LPS) fragments from bacterial cell walls that contaminate peptides during synthesis or lyophilisation if sterile technique fails. Even trace endotoxin contamination triggers immune responses in animal models. Fever, cytokine release, skewed inflammatory markers. Which confounds experimental results in metabolic, reproductive, or neuroendocrine studies where kisspeptin is commonly used. The COA must list endotoxin content in Endotoxin Units per milligram (EU/mg), measured via Limulus Amebocyte Lysate (LAL) assay.

For research-grade peptides intended for injection (subcutaneous, intravenous, or intracerebroventricular), endotoxin levels must be <1 EU/mg. Pharmaceutical-grade standards require <0.25 EU/mg. If the COA states 'Endotoxin: <10 EU/mg' or lists no endotoxin data at all, the peptide is not suitable for injectable research without additional purification. Suppliers producing peptides for in vitro use only may skip endotoxin testing entirely. Confirm the intended use case matches your protocol before ordering.

Red Flag: Missing Endotoxin Data on Injectable Peptides

If your COA lists HPLC purity and mass spec but omits endotoxin testing, contact the supplier immediately. Endotoxin contamination isn't visible. You can't detect it by appearance, and it doesn't affect purity measurements. A peptide can be 99% pure by HPLC and still contain endotoxin levels high enough to invalidate in vivo studies. At Real Peptides, every batch undergoes LAL endotoxin testing with results documented on the COA. Because injectable-grade research requires it.

Kisspeptin COA: Test Comparison

Key Takeaways

• Mass spectrometry confirms molecular weight within ±0.5 Da. This verifies you received the correct peptide sequence, not a synthesis error or wrong compound.
• HPLC purity ≥98% is the research-grade standard. Anything below 95% contains excessive impurities that skew concentration calculations and experimental outcomes.
• Endotoxin levels must be <1 EU/mg for injectable-grade peptides. Higher contamination or missing endotoxin data disqualifies the batch for in vivo research.
• The chromatogram visual on the COA shows impurity distribution. One tall dominant peak is ideal; multiple peaks of similar height indicate poor purification.
• Purity varies between batches from the same supplier. Always read the COA for your specific batch number instead of assuming consistency across orders.
• Peptide content by UV absorbance should match the vial label within ±10%. Greater variance means underfilled vials or degradation during storage.

What If: Kisspeptin COA Scenarios

What If the Observed Mass Doesn't Match the Expected Mass?

Contact the supplier immediately before reconstituting the peptide. A mass discrepancy >2 Da from the expected molecular weight means you either received the wrong peptide, a deletion sequence missing amino acids, or a synthesis batch with unintended modifications like oxidation or acetylation. Do not proceed with experiments. Molecular weight mismatch invalidates the entire batch for kisspeptin research. Request a replacement vial with verified mass spec results or a full refund. Reputable suppliers like Real Peptides will retest suspect batches and issue corrected COAs within 48–72 hours.

What If HPLC Purity Falls Below 95%?

Decide whether your research protocol tolerates lower purity before using the peptide. Purity between 90–95% is acceptable for preliminary dose-finding studies or in vitro receptor screening where small impurity percentages don't significantly affect outcomes. But for dose-response curves, pharmacokinetic studies, or any work requiring precise molar concentrations, purity <95% introduces systematic error. You're calculating doses based on stated peptide content, but 5–10% of that mass is inactive impurities. Either adjust your concentration calculations to account for stated purity or request a higher-purity replacement batch. Most suppliers offer tiered pricing: 95% purity costs less than 98%, which costs less than 99%. Confirm the grade matches your needs upfront.

What If the COA Lists No Endotoxin Data?

Ask the supplier whether endotoxin testing was performed but omitted from the COA, or whether the peptide is intended for in vitro use only and was never tested. If the peptide is marketed for injectable research and lacks endotoxin data, consider it non-compliant for in vivo protocols. Endotoxin contamination at levels as low as 5 EU/mg can activate macrophages and elevate circulating cytokines, confounding metabolic and neuroendocrine endpoints that kisspeptin studies frequently measure. You cannot visually detect endotoxin. The peptide will look perfectly normal. Switch suppliers or request endotoxin testing via an independent lab before injecting.

The Unflinching Truth About Kisspeptin COAs

Here's the honest answer: most suppliers issue COAs as compliance documents, not quality assurance. The COA proves they ran the tests. It doesn't prove they ran them correctly or interpreted the results with the stringency your research requires. We've reviewed COAs listing '98% purity by HPLC' where the attached chromatogram showed a main peak at 92% AUC and multiple impurity peaks totalling 8%. The stated purity didn't match the visual data. In another case, a supplier listed endotoxin as '<5 EU/mg' for an injectable peptide. Technically passing their internal threshold but five times higher than pharmaceutical-grade limits. The peptide shipped, the COA looked professional, and the researcher didn't notice until unexplained inflammatory markers appeared in their model.

Reading a kisspeptin COA correctly means verifying that every test result matches both the stated specification and the analytical evidence provided. If the chromatogram contradicts the purity claim, trust the chromatogram. If endotoxin data is missing, assume contamination until proven otherwise. If molecular weight drifts outside acceptable variance, stop and request retesting. The COA is not a certificate of trust. It's a dataset. Treat it like one.

What Separation Between COA Versions Reveals About Supplier Standards

One pattern we've observed across peptide suppliers: batch-to-batch COA consistency correlates directly with manufacturing quality control. Suppliers with tight process controls issue COAs where HPLC purity varies by <1% between batches (98.2%, 98.5%, 98.1%). Suppliers with inconsistent synthesis produce batches ranging from 95% to 99% purity with no clear pattern. That variance signals process drift, inadequate purification optimisation, or rushed production timelines. If you're ordering kisspeptin repeatedly for long-term studies, compare COAs across three consecutive batches. Purity swings >3% batch-to-batch suggest the supplier prioritises speed over reproducibility.

Another overlooked detail: COA formatting and completeness. A legitimate research supplier includes the testing lab name, analyst initials, test method references (e.g., 'USP <621> Chromatography'), and instrument calibration dates. A COA listing only results with no methodology or traceability is red-flagged for audit purposes. Regulatory bodies and institutional review boards increasingly require full analytical documentation for peptide sourcing. A one-page results summary without supporting data won't pass compliance review in 2026. At Real Peptides, every COA includes method references, analyst signatures, and third-party lab verification where applicable. Because reproducible research starts with verifiable materials.

Reading a kisspeptin COA isn't optional due diligence. It's the quality gate that prevents contaminated or mislabelled peptides from invalidating weeks of experimental work. The five minutes spent cross-checking mass spec, HPLC purity, and endotoxin levels before reconstitution can save you from discovering mid-protocol that your dose calculations were wrong or your control group was exposed to immune-activating contaminants. If the COA raises any doubts. Mismatched molecular weight, missing endotoxin data, purity <95% without disclosure. Resolve them with the supplier before proceeding. No experiment is improved by using questionable starting material.